Shots:
- AI is redefining compliance from reactive to predictive, as this April edition highlights how AI-powered systems are transforming regulatory oversight into a continuous, real-time, and data-driven function, enabling early risk detection, automated audits, and smarter regulatory collaboration across the pharma value chain.
- Strategic dealmaking and AI partnerships shape industry momentum, with March witnessing high-value acquisitions and collaborations led by companies like Biogen, Eli Lilly and Company, and Merck & Co., alongside growing investment in AI-driven discovery and precision genomics, signaling a strong push toward next-generation innovation and pipeline expansion.
- Innovation meets leadership and next-gen therapeutics through Robert M. Davis’s strategic vision at MSD, breakthroughs in programmable biology by Manifold Bio, and the continued impact of therapies like Eliquis, capturing how science, AI, and leadership are converging to reshape the future of global healthcare.
